Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Intangibles (2022 - 2025)

Coeptis Therapeutics Holdings has reported Intangibles over the past 4 years, most recently at $361250.0 for Q4 2025.

  • Quarterly results put Intangibles at $361250.0 for Q4 2025, down 33.33% from a year ago — trailing twelve months through Dec 2025 was $361250.0 (down 33.33% YoY), and the annual figure for FY2025 was $361250.0, down 33.33%.
  • Intangibles for Q4 2025 was $361250.0 at Coeptis Therapeutics Holdings, down from $406406.0 in the prior quarter.
  • Over the last five years, Intangibles for COEPW hit a ceiling of $3.6 million in Q4 2022 and a floor of $361250.0 in Q4 2025.
  • Median Intangibles over the past 4 years was $541875.0 (2024), compared with a mean of $1.7 million.
  • Peak annual rise in Intangibles hit 33.33% in 2025, while the deepest fall reached 33.33% in 2025.
  • Coeptis Therapeutics Holdings' Intangibles stood at $3.6 million in 2022, then dropped by 21.1% to $2.8 million in 2023, then crashed by 80.68% to $541875.0 in 2024, then tumbled by 33.33% to $361250.0 in 2025.
  • The last three reported values for Intangibles were $361250.0 (Q4 2025), $406406.0 (Q3 2025), and $451563.0 (Q2 2025) per Business Quant data.